AR034231A1 - Composicion farmaceutica que contiene mosaprida y pancreatina - Google Patents

Composicion farmaceutica que contiene mosaprida y pancreatina

Info

Publication number
AR034231A1
AR034231A1 ARP020101852A ARP020101852A AR034231A1 AR 034231 A1 AR034231 A1 AR 034231A1 AR P020101852 A ARP020101852 A AR P020101852A AR P020101852 A ARP020101852 A AR P020101852A AR 034231 A1 AR034231 A1 AR 034231A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
pancreatin
composition containing
containing mosapride
mosapride
Prior art date
Application number
ARP020101852A
Other languages
English (en)
Inventor
Juan Augusto Vergez
Marcelo A Ricci
Joaquina Faour
Original Assignee
Osmotica Argentina S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osmotica Argentina S A filed Critical Osmotica Argentina S A
Publication of AR034231A1 publication Critical patent/AR034231A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Abstract

Una composición farmacéutica que contiene mosaprida, pancreatina y opcionalmente simeticona y es utilizada para el tratamiento, prevención o alivio de los síntomas de un desorden gastrointestinal. La composición farmacéutica es provista en una forma de dosificación.
ARP020101852A 2001-05-23 2002-05-20 Composicion farmaceutica que contiene mosaprida y pancreatina AR034231A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/864,767 US6676933B2 (en) 2001-05-23 2001-05-23 Pharmaceutical composition containing mosapride and pancreatin

Publications (1)

Publication Number Publication Date
AR034231A1 true AR034231A1 (es) 2004-02-04

Family

ID=25344028

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020101852A AR034231A1 (es) 2001-05-23 2002-05-20 Composicion farmaceutica que contiene mosaprida y pancreatina

Country Status (3)

Country Link
US (1) US6676933B2 (es)
AR (1) AR034231A1 (es)
UY (1) UY27296A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004523513A (ja) * 2001-01-12 2004-08-05 イノベーション・ベンチャーズ・エルエルシー 活性化木炭に基づく組成物及びアルコール含有飲料の消費に関連する二日酔いを低減するための方法
TW200418486A (en) * 2003-01-31 2004-10-01 Takeda Chemical Industries Ltd Solid preparation
ES2314646T3 (es) * 2004-03-22 2009-03-16 Solvay Pharmaceuticals Gmbh Composiciones farmaceuticas por via de productos que contienen lipasa , en particular de pancreatina, que contienen tensioactivos.
TW200605920A (en) * 2004-07-28 2006-02-16 Dainippon Pharmaceutical Co Film coating tablet
KR101038403B1 (ko) 2004-07-28 2011-06-01 다이닛본 스미토모 세이야꾸 가부시끼가이샤 복수의 층을 갖는 필름-코팅된 정제
US7153504B2 (en) * 2004-07-30 2006-12-26 Can Technologies, Inc. Stabilized pancreas product
EP1913138B1 (en) * 2005-07-29 2016-08-24 Abbott Laboratories GmbH Processes for the manufacture of pancreatin powder with low virus content
US9198871B2 (en) * 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US20070077836A1 (en) * 2005-09-30 2007-04-05 General Electric Company Methods and apparatus for stabilizing exposed fabric edge
US8071089B2 (en) * 2005-11-01 2011-12-06 Bio-Cat, Inc. Composition with a fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrosis as well as people suffering from pancreatic lipase insufficiency
AU2006309539A1 (en) * 2005-11-04 2007-05-10 Ajinomoto Co., Inc. Gastrointestinal function promoter
US10072256B2 (en) * 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
EP2236546B1 (en) * 2006-10-31 2011-12-28 Surmodics Pharmaceuticals, Inc. Speronized polymer particles
AU2008242703B2 (en) * 2007-04-19 2011-08-18 Concert Pharmaceuticals Inc. Deuterated morpholinyl compounds
US20090130063A1 (en) * 2007-11-15 2009-05-21 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
KR101143997B1 (ko) * 2010-03-04 2012-05-09 한미사이언스 주식회사 유산균 제제 및 5-ｈｔ4 수용체 효능제를 함유하는 경구 투여용 복합 제제 및 이의 제조방법
MX2010012479A (es) * 2010-11-16 2012-05-16 Posi Visionary Solutions Llp Composicion farmaceutica de administracion oral para el tratamiento del sindrome de intestino irritable, a base de un modificador de la motilidad intestinal, un agente que previene la retencion de gases y enzimas digestivas y proceso para su preparacion.
ITMI20120131A1 (it) * 2012-02-01 2013-08-02 Probiotical Spa Batteri probiotici microincapsulati multistrato, loro produzione ed uso
EP3162371A1 (en) * 2015-10-27 2017-05-03 Przemyslaw Taciak A composition comprising simethicone, gastric acid-neutralizing substances and gastric enzyme(s) (e.g. pancreatine) for use in the treatment of digestive disorders
US11206841B2 (en) 2016-09-09 2021-12-28 International Agriculture Group, LLC Yogurt product from high starch fruits
MA46207A (fr) 2016-09-09 2019-07-17 Int Agriculture Group Llc Alternative au cacao naturel et ses procédés de production
MX2017001714A (es) * 2017-02-07 2018-08-06 Rhein Siegfried Sa De Cv Composicion de liberacion rapida de cinitaprida y simeticona y proceso para prepararla.
WO2019064112A1 (en) * 2017-09-29 2019-04-04 Johnson & Johnson Consumer Inc. SOLID PARTICLES OF SIMETHICONE AND THEIR DOSAGE FORM
CN110721151B (zh) * 2019-11-29 2023-09-12 远大生命科学(武汉)有限公司 一种西甲硅油复方液体组合物及其制备方法和应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0707492A1 (en) 1993-07-06 1996-04-24 Merck & Co. Inc. H 2? antagonist-gastrointestinal motility agent combinations

Also Published As

Publication number Publication date
US20030007962A1 (en) 2003-01-09
UY27296A1 (es) 2003-04-30
US6676933B2 (en) 2004-01-13

Similar Documents

Publication Publication Date Title
AR034231A1 (es) Composicion farmaceutica que contiene mosaprida y pancreatina
ES2552639T3 (es) Uso combinado de valsartán y bloqueantes de los canales de calcio para fines terapéuticos
ECSP056229A (es) Una composición farmacéutica que comprende formas polimórficas de 3-(4-amino-1-oxo-1.3 dyhidro-isoindol-2-il)-piperidina-2,6-diona para el tratamiento y manejo de cánceres
ECSP055525A (es) Inhibidores de cinasas de tirosina
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
BR0109198A (pt) Emplastro com filtro ultravioleta
MX9706769A (es) Formas de dosificacion farmaceutica que comprenden un inhibidor de la bomba de protones y un agente procinetico.
AR029763A1 (es) Uso de una combinacion de una nsaid y un inhibidor de quinasa egfr para la manufactura de un medicamento para el tratamiento o inhibicion de polipos colonicos y cancer colorectal, composicion farmaceutica y medicamento
AR038527A1 (es) Forma de dosificacion que contiene un inhibidor de la pde 4 como ingrediente activo
CY1112738T1 (el) Μια συνδυασμενη συνθεση που περιεχει ιβουπροφαινη και παρακεταμολη
CO5700709A2 (es) Forma de administracion de ibuprofeno sodico
CL2008003941A1 (es) Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden compulsivo obsesivo.
BR9807655A (pt) Uso de inibidores de lipase gastrintestinal.
ECSP045498A (es) "difenilazetidinonas sustituidas en anillo, metodo para su producción, medicamentos que comprenden estos compuestos y su uso"
CY1106845T1 (el) Χρηση της φλουμαζενιλης για την παρασκευη ενος φαρμακου για την αγωγη της εξαρτησεως απο την κοκαϊνη
AR052830A1 (es) Regimen de cladribina para tratar esclerosis multiple
AR032642A1 (es) Composiciones quimioterapicas de paclitaxel en microemulsion con mayor biodisponibilidad oral.
BR0213181A (pt) Combinações de inibidor de cox-2
NO20035602D0 (no) Sammensetning som omfatter en PDE-4-inhibitor og H1- reseptorantagonist, samt anvendelse derav til fremstilling av et medikament forbehandling av åndedrettsykdommer
AR036085A1 (es) Formas de dosificacion y procedimiento para su fabricacion
TR199802351T2 (xx) Topikal kullanım için bir veya birden fazla lokal anestezik ve anti-vajinit maddeler ihtiva eden anti-vajinit bileşimi.
ES2184341T3 (es) Un metodo para la prevencion y el tratamiento de la disfuncion del miocardio.
AR039232A1 (es) Una formulacion farmaceutica que comprende al menos un compuesto seleccionado del grupo formado por hipnoticos no barbituricos y no benzodiacepinicos, y melatonina
AR043327A1 (es) Uso de inhibidores de quinurenina 3- hidroxilasa para el tratamiento de la diabetes
AR034142A1 (es) Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion

Legal Events

Date Code Title Description
FG Grant, registration
FG Grant, registration